Antiphospholipid syndrome

Transl Res. 2020 Nov:225:70-81. doi: 10.1016/j.trsl.2020.04.006. Epub 2020 May 12.


Antiphospholipid syndrome is one of the more common acquired causes of hypercoagulability. Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia). Classification criteria include 3 different antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, and anti-beta 2 glycoprotein I. Management includes both preventive strategies (low-dose aspirin, hydroxychloroquine) and long-term anticoagulation after thrombosis.

Publication types

  • Review

MeSH terms

  • Antibodies, Antiphospholipid / analysis
  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome / complications*
  • Antiphospholipid Syndrome / drug therapy
  • Antiphospholipid Syndrome / immunology
  • Humans


  • Antibodies, Antiphospholipid
  • Anticoagulants